INTRODUCTION
============

RNA functions as an intermediate molecule in the transfer of genetic information from DNA to protein. Noncoding RNAs (ncRNAs) are defined as RNAs that do not code proteins; they include all traditional classes of RNAs (except for mRNAs) such as rRNAs, tRNAs, and snRNAs, as well as the more recently discovered microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). With the advent of robust high throughput sequencing technologies and advances in bioinformatics, thousands of long and short ncRNAs have been discovered in the past decade in prokaryotes, eukaryotes, and viruses. These ncRNAs encompass transcripts of different sizes, from processed small RNAs \~20-30 bases in length to lncRNAs that are hundreds or even thousands of bases long \[[@B1]\]. These recently discovered ncRNAs represent a new paradigm of gene regulation. In particular, many miRNAs and lncRNAs have been reported to regulate both normal development and tumorigenesis in the mammary gland \[[@B2]\].

Circular RNA (circRNA) is a recently discovered ncRNA. CircRNA isoforms have largely gone unnoticed since their discovery in 1979, with some notable exceptions \[[@B3]\]. Recent studies by two independent teams demonstrated that a human circRNA running antisense to the cerebellar degenerationrelated protein 1 (CDR1) locus functions as a sponge for miR-7 \[[@B4][@B5]\]. Interestingly, miR-7 inhibits the epithelial-mesenchymal transition and metastasis of breast cancer, and sensitizes cells to DNA damage \[[@B6][@B7]\], which indicates that circRNAs may play profound roles in breast cancer. A circRNA transcribed from the Sry gene was also reported to act as a miR-138 sponge \[[@B8]\]. These two examples represent a strong paradigm for circRNA function, and have therefore attracted attention towards circRNAs. Growing evidence indicates that circRNAs, which are expressed from a large fraction of human, mouse, zebrafish, *Caenorhabditis elegans*, and fruit fly genes, constitute the major RNA isoform from these genes \[[@B9][@B10][@B11][@B12]\]. However, no information on mammary gland circRNAs has been reported.

Breastfeeding is not only beneficial to infants, but also provides many health benefits to mothers \[[@B13]\]. The maternal health benefits include decreased postpartum bleeding, more rapid uterine involution, decreased menstrual blood loss, increased child spacing, earlier return to prepregnancy weight, and possible decreased risk of hip fractures and osteoporosis in the postmenopausal period \[[@B13]\]. One of the most notable maternal health benefits is a decreased risk of breast cancer, which has been demonstrated by several groups using different methods \[[@B14]\]. These findings suggest that breastfeeding affects biological processes in the mammary gland. However, the molecular mechanisms underlying the role of breastfeeding in breast cancer prevention remain unclear. Accordingly, an understanding of the molecular landscape of the normal breast during lactation is critical for breast cancer prevention.

In the present study, we investigate the circRNA expression pattern in the lactating mammary gland to provide a basis for comparison between breast cancer profiles, and for selection of representative circRNA candidates for future functional characterization in breast development and breast cancer.

METHODS
=======

Animal material
---------------

Mammary gland tissue samples from ten Sprague Dawley rats (*Rattus norvegicus*) fifth parturition were obtained from Vital River Laboratories (Beijing, China). Lactating mammary glands were harvested from five rats at day 1 and 7 postpartum and frozen in liquid nitrogen for subsequent extraction of RNA. All samples were obtained in accordance with the experimental procedures guideline of Jiangsu Normal University, and all experimental protocols were approved by the Animal Ethics Committee of Jiangsu Normal University.

RNA isolation and RNase R enrichment
------------------------------------

Total RNA was extracted using Trizol (Life Technologies, Carlsbad, USA), and treated with DNase I. The RNase R enrichment protocol was modified from a previous report \[[@B11]\]. Each total RNA sample (20 µg) was depleted for ribosomal RNAs using the RiboMinus kit (Life Technologies), and then subjected to RNase R treatment. RiboMinus RNA was incubated for 15 minutes at 37℃, with or without (control) 3 U/µg of RNase R (Epicentre Biotechnologies). RNA was subsequently purified by phenol-chloroform extraction, and divided into two parts, one of which was used to prepare libraries for sequencing, using Illumina\'s whole-transcriptome RNA sequencing protocols (Illumina, San Diego, USA). The Illumina Hiseq2000 System was used to perform sequencing runs for RNA sequencing. The other was reverse transcribed using the SuperScript III FirstStrand Synthesis System (Life Technologies) with random hexamers, according to the manufacturer\'s instructions.

Computational pipeline for prediction of circRNAs
-------------------------------------------------

The rat reference genome was downloaded from the National Center for Biotechnology Information (NCBI) genome browser (<ftp://ftp.ncbi.nlm.nih.gov/genomes/R_norvegicus/>). Sequencing reads from each pooled sample were mapped independently using the short-read mapper Bowtie 2 \[[@B15]\]. Reads aligning contiguously and full length to the genome were discarded. We extracted 20-mers from both ends and aligned them independently to find unique anchor positions within spliced exons from the remaining reads. Anchors that aligned in the reverse orientation (head-to-tail) indicated circRNA splicing. We extended the anchor alignments such that the complete read aligns and the breakpoints were flanked by GU/AG splice sites. Ambiguous breakpoints were discarded. More information can be found in a previous report \[[@B5]\].

Gene ontology terms of circRNA-producing genes
----------------------------------------------

The DAVID tool (National Institute of Allergy and Infectious Diseases, Bethesda, USA) was used for enrichment of gene ontology (GO) terms of circRNA-producing genes.

Detecting putative miRNA binding sites
--------------------------------------

FASTA files of rat miRNAs were obtained from miRBase release 20.0 (<http://www.mirbase.org/>). Only mature miRNAs were considered for seed analysis. The miRNAs were aligned with circRNAs. A putative target site of a miRNA is a 6-nucleotide-long sequence in the genome that represents the reverse complement of nucleotides 2-7 of the mature miRNA sequence.

Modeling of linear to circular expression
-----------------------------------------

In order to test the global relationship between the circRNAs and linear RNAs, we fit a Poisson model per gene modeling circular expression by reads per kilobase of exon model per million mapped reads (RPKM) to poly(A) gene expression using SPSS version 19.0 (IBM Corp., Armonk, USA).

Quantitative reverse-transcription polymerase chain reaction analysis
---------------------------------------------------------------------

cDNAs of mock and RNase R-treated RNA were diluted with water and used as a template for polymerase chain reaction (PCR). In order to validate the unpolyadenylated status of circRNAs, the total RNAs were reverse-transcribed with oligo-dTs and random hexamer primers, and the cDNAs were subjected to qPCR. Standard PCR was performed using Taq DNA polymerase (New England Biolabs, Beverly, USA), and quantitative PCR was performed using SYBR Green Mix (Roche, Basel, Switzerland) on a StepOne plus Real-Time PCR System. qPCR Ct values were calculated automatically using the manufacturer\'s software. The PCR primers are listed in [Supplementary Table 1](#S1){ref-type="supplementary-material"} (available online). PCR products were directly Sanger-sequenced in both directions using amplification primers.

RESULTS
=======

CircRNA transcriptome composition
---------------------------------

We obtained 11,853,653 and 11,970,307 clean sequence reads of 86 nucleotides from the two RNase R-treated RiboMinus mammary gland RNA pools. Nearly half (45%) of the clean reads were predicted as circRNAs, and most of the circRNAs were transcribed from gene-containing regions covering 1,569 genes. These data were consistent with findings from previous studies that identified circRNAs from mainly exons and introns of gene-containing regions ([Figure 1](#F1){ref-type="fig"}) \[[@B3][@B4][@B5][@B9][@B10][@B11]\].

CircRNA expression patterns
---------------------------

We detected 6,824 and 4,523 circRNAs from lactating mammary glands at day 1 (D1) and 7 (D7) postpartum, respectively. The length of circRNAs varied from 66 nt to 1,955 nt. Numerous circRNAs seemed to be specifically expressed at different lactation stages, as only 1,314 circRNAs were detected at both lactation stages.

The circularization of circRNAs and their relative expression levels, as obtained from RNA-sequencing, were validated. Inward and outward facing primers were designed against 11 randomly selected representative transcripts. Each primer pair amplified a single, distinct product of the expected size and sequence. RNase R resistance of all 11 novel backsplice events was apparent following RNase R treatment, whereas the abundance of linear RNAs was found to decrease ([Table 1](#T1){ref-type="table"}). Moreover, oligo-dT priming for reverse transcription resulted in significantly lower levels of backspliced products relative to poly(A)-containing transcript levels, indicating that these species were not polyadenylated ([Table 1](#T1){ref-type="table"}). The difference in the expression of the 11 circRNAs between the two time points was also confirmed by qPCR ([Supplementary Figure 1](#S2){ref-type="supplementary-material"}).

In order to exclude the possibility that circRNAs might be the result of the background \"noise\" level of dysfunctional splicing, we analyzed the relationship between linear RNA isoform expression from a given gene and the probability of detecting a circRNA isoform from that gene. We did not find any correlation between the expressions of the two RNA isoforms ([Figure 2](#F2){ref-type="fig"}).

Many circRNAs are derived from kinase genes
-------------------------------------------

In order to investigate the function of circRNAs, the GO term enrichment of the set circRNA-producing genes was analyzed using the DAVID tool. The top five annotation clusters, summarized in [Table 2](#T2){ref-type="table"}, involved nucleotide and ATP binding, nuclear lumen, GTPase regulator activity, ion binding and protein kinase activity.

Docking sites for miRNAs in circRNAs
------------------------------------

In the present study, 716 out of 728 mature rat miRNAs were predicted to have docking sites in the circRNAs detected in the rat mammary gland. Only a few circRNAs were predicted to have many miRNA-binding sites, which indicated that circularization was not a global feature under selection in the sequence of the thousands of circRNAs profiled.

DISCUSSION
==========

Previous studies have identified circRNAs mainly from exons and introns in gene-containing regions \[[@B3][@B4][@B5][@B9][@B10][@B11]\]. In the present study, circRNAs were not only identified from gene containing regions, but also from intergenic regions. The circRNAs distributed in noncoding regions accounted for \~70% of the total circRNAs, including those from intronic and intergenic regions, of which intronic circRNAs accounted for more than 40%. This is similar to the expression pattern of other ncRNAs \[[@B16]\].

The top five annotation clusters involved nucleotide and ATP binding, nuclear lumen, GTPase regulator activity, ion binding and protein kinase activity. As the activation of virtually all cell-surface receptors leads directly or indirectly to changes in protein phosphorylation via activation of protein kinases, the circRNAs derived from protein kinase-encoding genes may also be functional \[[@B17]\]. We also analyzed mouse and human circRNA data from several tissues \[[@B5][@B10][@B11]\]. Notably, DAVID analysis revealed an enrichment of protein kinases and related proteins among the set of genes producing circRNAs in the tissues of various species. This finding further verified that circRNAs show a high degree of evolutionary conservation, suggesting that they might have important biological functions.

In the present study, most circRNAs were transcribed from protein-coding gene regions, which indicated a circular preference or specificity of some genes. The set of genes producing circRNAs in the tissues of various mammal species were all enriched for protein kinases and related proteins \[[@B5][@B11]\]. As shown in [Table 3](#T3){ref-type="table"}, seven of the 10 most highly expressed circRNA families were transcribed from seven different protein-coding gene regions. Interestingly, four of the protein-coding genes (Rev3l, IGSF11, MAML2, and LPP) were reported to be involved in carcinogenesis. Rev3l, which encodes an error-prone DNA polymerase Pol ζ subunit, is critical for embryonic development and maintenance of genome stability \[[@B18][@B19]\]. Loss of Rev3l enhances spontaneous mammary tumorigenesis, and genetic variation in the Rev3l gene is reported to affect the development and progression of breast cancer \[[@B20][@B21]\]. The expression of the immunoglobulin superfamily 11 gene (IGSF11) was elevated in colorectal cancers and hepatocellular carcinomas as well as in intestinal-type gastric cancers, and IGSF11 is suggested to be a potential target for cancer immunotherapy \[[@B22]\]. MAML2, a member of the mastermind-like (MAML) family, functions as an essential coactivator of NOTCH in regulating a variety of malignancies \[[@B23]\]. There is increasing evidence that lipoma preferred partner (LPP) plays an important role in the development of a variety of human cancers \[[@B24]\]. A recent report revealed that LPP, which was normally operative in cells of mesenchymal origin, could be co-opted by breast cancer cells during an epithelial-mesenchymal transition to promote their migration and invasion \[[@B25]\]. Expression levels of the circRNA families transcribed from the above-mentioned four genes were all remarkably higher than those in their linear counterparts. The abundance of circRNA family from Igsf11 was 1,700-fold higher than that of Igsf11 mRNA expressed in the mammary gland. These data indicate that although the functions of these circRNAs remain unclear, they are unlikely to be the result of background \"noise.\"

Recent reports have shown that, in mammals, circRNAs may function as miRNA sponges or compete against endogenous RNAs \[[@B4][@B5][@B6]\]. However, the enrichment of miRNA binding sites was not a global feature under selection in the sequence of the thousands of circRNAs profiled in the present study, which is consistent with the findings of a recent report \[[@B10]\]. However, we did identify a highly expressed circRNA that had several miRNA-binding sites. CircRNA_1093, with a short length of 108 bp, had 4 miR-342-3p binding sites. Notably, miR-342 was recently reported to regulate BRCA1 expression in breast cancer \[[@B26]\]. Therefore, we speculate that these circRNAs may be involved in the regulation of oncogenesis. In addition to their general regulatory functions in normal development, miR-200 and let-7 families are relatively well characterized in breast cancer initiation and self-renewal \[[@B27][@B28]\]. A total of 3,100 circRNAs possess putative binding sites for members of the miR-200 family, of which 599 circRNAs have more than 10 binding sites, and a total of 2,539 circRNAs have putative binding sites for members of the let-7 family, of which 932 circRNAs have more than 10 binding sites. The high stability of circRNA in cells \[[@B11]\] suggests that they might be involved in the regulation of breast cancer via miRNAs. However, the potential genome-wide interplay between miRNAs and circRNAs needs further experimental and computational investigation.

Although the function of circRNAs remains largely unclear, an association between circRNAs and cancers has been reported. There is a global reduction in circRNA abundance in colorectal cancer cell lines and cancer compared with that in normal tissues, revealing a negative correlation between global circRNA abundance and proliferation and cancer \[[@B29]\]. Additionally, typical circRNAs were found to be show a significantly lower expression in gastric cancer tissues than in the paired adjacent nontumorous tissues \[[@B30]\]. These findings indicate that circRNA is a promising biomarker for cancer diagnosis. In the present study, a total of 6,824 and 4,523 circRNAs were identified by deep RNA sequencing from normal rat mammary glands at two lactation stages. These results provide the basis for comparison of breast cancer profiles and for selection of representative circRNA candidates for future functional characterization in breast development and breast cancer.
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###### The polymerase chain reaction primers for circular RNA validation

![](jbc-18-235-s001)

  circRNAs                 Gene                     Outward primer           Inward primer
  ------------------------ ------------------------ ------------------------ ------------------------
  circRNA_555              *Tc2n*                   GGCACAATACCTTCCAAGTTCA   AAGAAGACACGCTTACTGAAGG
  CCTTCAGTAAGCGTGTCTTCTT   TGAACTTGGAAGGTATTGTGCC                            
  circRNA_127              *Arhgap10*               GAACCTTATCGCTGCCACCAA    GCACAGTTGGATAAGATGGGAT
  GCACCGTTCATCATCAGTCTCA   ACTGCTTCCTTTCCTCTTCTGA                            
  circRNA_3385             *Hnrnpm*                 ATTGATGCCAACCACCTGAACA   CAGGATGAGAGGGCTTTACCAA
  GCTCCACCTCCTCCTTGCTT     ATGTCTGCTCGGACCACCA                               
  circRNA_659              *Cox4i1*                 TATGTTGATCGGCGTGACTACC   TTCAGTGTACCGCATCCAGTT
  CCACCACTGTCTTCCACTCATT   AGTCACGCCGATCAACATAAGA                            
  circRNA_10008            *Zmynd11*                AGGCATATTGACTCCACTGACA   GAACCTTATCGCTGCCACCAA
  AACTGGCTGGCTCGCTTCT      GCACCGTTCATCATCAGTCTCA                            
  circRNA_537              *Tead1*                  GCTACCGCCATCCACAACAA     TCACATTCAGGTTCTTGCCAGA
  GGCTGTCCTGTCTGTATCATCC   TTGTCTTTCCCGTCCTCAGTTT                            
  circRNA_388              *Gnaq*                   CCTTCCTATCTGCCTACACAAC   GGCAAGAGTACCTTCATTAAGC
  CTCTCCTCCATTCGGTTCTCAT   AGCACATCAGTCACCTACAAC                             
  circRNA_15703            *Nars*                   ACAGGTTACGAAGGCAAGGAA    AAAGAGCCGTTTCCCACCATTT
  ACGCTACTCTCAGTGGACAAG    AACAACGCCATGTGCTCAGAA                             
  circRNA_7070             *Hdac4*                  AAGCACAAGCAACAGTTCCAG    GGGAATTTGGAGCGTGTTGGA
  GCCTCTACTTCTTCCTCCTCAC   CCACTGGCAGCGTCTTGTAA                              
  circRNA_36159            *Eef1a1*                 CTGATTGTTGCTGCTGGTGTTG   GCTTCTCTGACTACCCTCCACT
  TGTATGGTGGCTCGGTGGAA     GCAGCATCACCAGACTTCAAGA                            
  circRNA_4815             *Clmn*                   GCACCGACTCAGATTCTTCCTA   ACCGACTCAGATTCTTCCTACC
  GACCGCCACACCATACTTCC     GATGCTAACCAGCTTGACTTCC                            

circRNAs=circular RNAs.

###### Supplementary Figure 1

Correlation of relative expression value quantified by qPCR with that analyzed by RNA sequencing. Y-axis, representing the circRNA abundance differentiation between rat mammary glands at day 1 and day 7 as measured by qPCR; X-axis, representing the circRNA abundance differentiation between rat mammary glands at day 1 and day 7 as measured by RNA-sequencing.

![The distribution of circular RNAs in the genome. (A) Rat mammary gland library at day 1 postpartum. (B) Rat mammary gland library at day 7 postpartum.\
CDS=coding sequences.](jbc-18-235-g001){#F1}

![Quantitative regulation of circular to linear isoform. No genome-wide trend between circular expression and linear transcript expression as measured by log PolyA reads per kilobase of exon model per million mapped reads (RPKM).\
Y axis=RPKM for circular RNA; X axis=log PolyA RPKM of linear isoform.](jbc-18-235-g002){#F2}

###### Quantitative polymerase chain reaction validation of circular RNAs by different reverse transcription primers and RNase R treatment

![](jbc-18-235-i001)

  circRNAs        Reverse transcription treatment^\*^   RNase R treatment^†^                  
  --------------- ------------------------------------- ---------------------- -------------- -------------
  circRNA_555     -4.41 (0.29)                          -0.08 (0.08)           -0.74 (0.11)   3.99 (0.04)
  circRNA_127     -3.57 (2.46)                          -2.34 (1.87)           -0.36 (0.56)   5.25 (0.43)
  circRNA_3385    0.43 (1.45)                           -0.90 (0.31)           0.06 (0.10)    6.16 (0.42)
  circRNA_659     -4.55 (0.57)                          1.06 (0.01)            0.61 (0.62)    9.10 (0.42)
  circRNA_10008   -7.34 (1.51)                          -2.16 (0.07)           0.44 (0.33)    4.16 (0.56)
  circRNA_537     -5.45 (0.32)                          -6.20 (0.22)           0.38 (0.53)    2.06 (0.11)
  circRNA_388     -5.24 (1.40)                          -2.93 (1.59)           -0.19 (0.56)   2.95 (0.11)
  circRNA_15703   -3.84 (0.69)                          -1.98 (0.05)           1.51 (0.54)    5.77 (0.39)
  circRNA_7070    -2.79 (0.61)                          -2.69 (0.24)           -2.48 (0.58)   3.19 (0.22)
  circRNA_36159   -0.32 (0.68)                          -1.99 (0.04)           0.23 (0.34)    7.98 (0.09)
  circRNA_4815    -3.31 (1.51)                          -4.31 (0.29)           -1.37 (0.74)   1.96 (0.52)

circRNAs=circular RNAs.

^\*^The values were ΔCT values between random hexamer primer generated templates and oligo-dT generated templates with standard deviation in bracket; ^†^The values were ΔCT values between templates from RNase R treated RNA and mock treated RNA with standard deviation in bracket.

###### Gene ontology term enrichment of circular RNA generating genes

![](jbc-18-235-i002)

  Category (enrichment score)                               Description                       Count   Fold enrichment   False discovery rate
  --------------------------------------------------------- --------------------------------- ------- ----------------- ----------------------
  Nucleotide and adenosine-triphosphate binding (6.60)      Purine nucleotide binding         87      1.78              7.79E-05
  Purine ribonucleotide binding                             84                                1.80    8.05E-05          
  Ribonucleotide binding                                    84                                1.80    8.51E-05          
  Nucleoside binding                                        77                                1.86    9.54E-05          
  Purine nucleoside binding                                 76                                1.85    1.46E-04          
  Nucleotide binding                                        98                                1.68    1.53E-04          
  Adenyl ribonucleotide binding                             72                                1.89    1.55E-04          
  Adenyl nucleotide binding                                 75                                1.86    1.56E-04          
  ATP binding                                               71                                1.91    1.57E-04          
  Nuclear lumen (4.88)                                      Nucleoplasm                       40      2.23              4.18E-03
  Membrane-enclosed lumen                                   59                                1.82    7.17E-03          
  Nuclear lumen                                             47                                1.97    1.38E-02          
  Intracellular organelle lumen                             55                                1.81    2.08E-02          
  Organelle lumen                                           56                                1.78    2.82E-02          
  Nucleoplasm part                                          26                                2.34    1.62E-01          
  GTPase regulator activity (3.63)                          Small GTPase regulator activity   19      3.53              1.05E-02
  Regulation of small GTPase mediated signal transduction   19                                3.37    2.35E-02          
  GTPase regulator activity                                 22                                2.76    7.08E-02          
  Nucleoside-triphosphatase regulator activity              22                                2.70    9.83E-02          
  Regulation of Ras protein signal transduction             15                                3.38    2.39E-01          
  Enzyme activator activity                                 16                                2.86    7.12E-01          
  GTPase activator activity                                 12                                3.37    1.24E+00          
  Regulation of GTPase activity                             9                                 3.83    3.93E+00          
  Regulation of Ras GTPase activity                         8                                 4.26    4.38E+00          
  Ion binding (3.53)                                        Zinc ion binding                  71      1.63              4.83E-02
  Transition metal ion binding                              84                                1.50    1.36E-01          
  Metal ion binding                                         116                               1.36    2.46E-01          
  Cation binding                                            116                               1.34    4.35E-01          
  Ion binding                                               116                               1.32    8.71E-01          
  Protein kinase activity (3.49)                            Phosphate metabolic process       54      2.17              1.92E-04
  Phosphorus metabolic process                              54                                2.16    2.04E-04          
  Phosphorylation                                           46                                2.19    1.54E-03          
  Protein amino acid phosphorylation                        41                                2.26    3.32E-03          
  Protein kinase activity                                   38                                2.26    7.63E-03          
  Protein serine/threonine kinase activity                  30                                2.55    9.75E-03          

ATP=adenosine triphosphatase; GTPase=guanosine triphosphatase.

###### The 10 most abundance co-expressed circular RNA families in rat mammary gland at day 1 and day 7

![](jbc-18-235-i003)

  Genomic region                     Day 1         Day 7          Gene                         
  ---------------------------------- ------------- -------------- ------------- -------------- ----------------
  NW_003812807: 1828679\...1829413   2,055.8 (1)   87.9 (1,019)   1,562.6 (1)   71.0 (1,310)   *Nip30*
  NW_003813123: 1588160\...1589235   569.9 (2)     3.9 (9,366)    556.2 (2)     3.4 (9,162)    *Rev3l*
  NW_003811247: 99932\...100069      515.5 (3)     ND             0             ND             Intergenic
  NW_003811537: 153458\...165077     172.7 (20)    2,408.2 (31)   365.8 (3)     1,919.2 (32)   *Rn45s*
  NW_003810754: 1053550\...1055309   513.0 (4)     0.3 (14,430)   342.0 (4)     0.2 (14,802)   *Igsf11*
  NW_003807897: 6882661\...6883299   423.6 (5)     6.9 (7,668)    65.7 (37)     8.6 (6,511)    *Phtf2*
  NW_003809175: 1605166\...1605873   373.7 (6)     ND             26.1 (72)     ND             Intergenic
  NW_003811373: 1201130\...1201246   362.6 (7)     ND             40.0 (51)     ND             Intergenic
  NW_003810582: 2592261\...2592708   320.6 (8)     8.1 (7,137)    5.8 (234)     7.0 (7,209)    *LOC100361417*
  NW_003809684: 1179751\...1180471   306.6 (9)     14.8 (5,128)   190.8 (5)     36.0 (2,520)   *Maml2*
  NW_003810792: 4017988\...4018799   299.9 (10)    7.1 (7,540)    196.3 (6)     9.0 (6,400)    *Lpp*
  NW_003812337: 587010\...587645     230.4 (14)    ND             232.0 (7)     ND             Intergenic
  NW_003809106: 939227\...940296     151.0 (22)    ND             217.4 (8)     ND             Intergenic
  NW_003806649: 2252840\...2253928   20.2 (150)    11.5 (2,073)   205.0 (9)     19.8 (2,924)   *Polr3g*
  NW_003806649: 2161597\...2161746   272.8 (11)    ND             200.2 (10)    ND             Intergenic

circRNA=circular RNA; linRNA=mRNA of the circular RNA generating gene; ND=not determined.

^\*^The number in bracket is the abundance ranking of a circRNA among the identified circular RNAs; ^†^The number in bracket is the abundance ranking of a mRNA among the expressed mRNAs.
